BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 8676625)

  • 1. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL.
    Johnson S; Smith AG; Löffler H; Osby E; Juliusson G; Emmerich B; Wyld PJ; Hiddemann W
    Lancet; 1996 May; 347(9013):1432-8. PubMed ID: 8676625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. The French Cooperative Group on Chronic Lymphocytic Leukemia.
    Semin Oncol; 1993 Oct; 20(5 Suppl 7):21-3. PubMed ID: 8235691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
    Leporrier M; Chevret S; Cazin B; Boudjerra N; Feugier P; Desablens B; Rapp MJ; Jaubert J; Autrand C; Divine M; Dreyfus B; Maloum K; Travade P; Dighiero G; Binet JL; Chastang C;
    Blood; 2001 Oct; 98(8):2319-25. PubMed ID: 11588025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia.
    Leporrier M
    Hematol J; 2004; 5 Suppl 1():S10-9. PubMed ID: 15079149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
    Levy V; Porcher R; Delabarre F; Leporrier M; Cazin B; Chevret S;
    J Clin Epidemiol; 2001 Jul; 54(7):747-54. PubMed ID: 11438417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial.
    Howard DR; Munir T; McParland L; Rawstron AC; Chalmers A; Gregory WM; O'Dwyer JL; Smith A; Longo R; Varghese A; Smith A; Hillmen P
    Health Technol Assess; 2017 May; 21(28):1-374. PubMed ID: 28628003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
    Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
    Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
    Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
    Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidation therapy with high-dose cyclophosphamide improves the quality of response in patients with chronic lymphocytic leukemia treated with fludarabine as induction therapy.
    Weiss MA; Glenn M; Maslak P; Rahman Z; Noy A; Zelenetz A; Scheinberg DA; Golde DW
    Leukemia; 2000 Sep; 14(9):1577-82. PubMed ID: 10995003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine plus cyclophosphamide for the treatment of advanced chronic lymphocytic leukemia.
    Schiavone EM; De Simone M; Palmieri S; Annunziata M; Pocali B; Copia C; D'Amico MR; Vecchio LD; Ferrara F
    Eur J Haematol; 2003 Jul; 71(1):23-8. PubMed ID: 12801295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.
    Flinn IW; Neuberg DS; Grever MR; Dewald GW; Bennett JM; Paietta EM; Hussein MA; Appelbaum FR; Larson RA; Moore DF; Tallman MS
    J Clin Oncol; 2007 Mar; 25(7):793-8. PubMed ID: 17283364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial.
    Elter T; Gercheva-Kyuchukova L; Pylylpenko H; Robak T; Jaksic B; Rekhtman G; Kyrcz-Krzemień S; Vatutin M; Wu J; Sirard C; Hallek M; Engert A
    Lancet Oncol; 2011 Dec; 12(13):1204-13. PubMed ID: 21992852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
    Kimby E; Brandt L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):224-30. PubMed ID: 11441934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
    Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
    N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
    O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
    J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-Hodgkin's lymphoma.
    Hendry L; Bowen A; Matutes E; Swansbury J; Catovsky D
    Leuk Lymphoma; 2004 May; 45(5):945-50. PubMed ID: 15291353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-Polish multicentre study.
    Kowal M; Dmoszyńska A; Lewandowski K; Hellmann A; Wegrzyn J; Skotnicki AB; Wołowiec D; Kuliczkowski K; Piszcz J; Kłoczko J; Roznowski K; Komarnicki M
    Leuk Lymphoma; 2004 Jun; 45(6):1159-65. PubMed ID: 15359995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
    Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
    J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.